Intercept Pharmaceuticals (DB:I4P) - Stock Price, News & Analysis

I4P Stock Overview

I4P fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	4/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 56.2% below our estimate of its fair value

Earnings are forecast to grow 42.37% per year

Earnings have grown 22.4% per year over the past 5 years

Trading at good value compared to peers and industry

Risk Analysis

Highly volatile share price over the past 3 months

Intercept Pharmaceuticals, Inc. Competitors

Formycon

XTRA:FYB

€827.2m

Biotest

XTRA:BIO3

€1.4b

Heidelberg Pharma

XTRA:HPHA

€103.9m

2invest

XTRA:2INV

€63.8m

Price History & Performance

Summary of all time highs, changes and price drops for Intercept Pharmaceuticals
Historical stock prices
Current Share Price	US$17.52
52 Week High	US$19.97
52 Week Low	US$8.16
Beta	0.88
11 Month Change	0.46%
3 Month Change	90.52%
1 Year Change	14.92%
33 Year Change	-45.23%
5 Year Change	-79.17%
Change since IPO	17.29%

Recent updates

Shareholder Returns

	I4P	DE Biotechs	DE Market
7D	-0.8%	-0.7%	-0.02%
1Y	14.9%	-17.2%	8.2%

Return vs Industry: I4P exceeded the German Biotechs industry which returned -23.1% over the past year.

Return vs Market: I4P exceeded the German Market which returned 5.9% over the past year.

Price Volatility

Is I4P's price volatile compared to industry and market?
I4P volatility
I4P Average Weekly Movement	22.8%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: I4P's share price has been volatile over the past 3 months.

Volatility Over Time: I4P's weekly volatility has increased from 15% to 23% over the past year.

About the Company

Founded	Employees	CEO	Website
2002	341	Jerry Durso	www.interceptpharma.com

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development.

Intercept Pharmaceuticals, Inc. Fundamentals Summary

How do Intercept Pharmaceuticals's earnings and revenue compare to its market cap?
I4P fundamental statistics
Market cap	€742.08m
Earnings (TTM)	-€53.66m
Revenue (TTM)	€296.65m

2.5x

P/S Ratio

-13.8x

P/E Ratio

Is I4P overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
I4P income statement (TTM)
Revenue	US$317.68m
Cost of Revenue	US$632.00k
Gross Profit	US$317.05m
Other Expenses	US$374.52m
Earnings	-US$57.47m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.37
Gross Margin	99.80%
Net Profit Margin	-18.09%
Debt/Equity Ratio	311.6%

How did I4P perform over the long term?

See historical performance and comparison

I4P Stock Overview

Rewards

Risk Analysis

Intercept Pharmaceuticals, Inc. Competitors

XTRA:FYB

€827.2m

XTRA:BIO3

€1.4b

XTRA:HPHA

€103.9m

XTRA:2INV

€63.8m

Price History & Performance

Recent News & Updates

Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA)

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Recent updates

Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA)

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Third quarter 2023 earnings released: US$0.066 loss per share (vs US$3.04 loss in 3Q 2022)

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Now 22% undervalued after recent price drop

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.68 loss in 2Q 2022)

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings released: US$0.77 loss per share (vs US$1.13 loss in 1Q 2022)

Full year 2022 earnings released: US$5.17 loss per share (vs US$2.87 loss in FY 2021)

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings released: US$3.04 loss per share (vs US$0.11 loss in 3Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Second quarter 2022 earnings released: US$0.68 loss per share (vs US$0.33 loss in 2Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Forecast to breakeven in 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Forecast to breakeven in 2024

Intercept Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis

Forecast breakeven date moved forward to 2022

First quarter 2022 earnings released: US$0.58 loss per share (vs US$1.22 loss in 1Q 2021)

Intercept Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2022

Intercept Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 02, 2022

Pomerantz Law Firm Announces the Filing of A Class Action Against Intercept Pharmaceuticals, Inc

Forecast to breakeven in 2024

Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH

Intercept Pharmaceuticals, Inc. Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$2.02 loss in 3Q 2020)

Intercept Pharmaceuticals, Inc. announced a financing transaction

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$1.92 loss in 2Q 2020)

Intercept Pharmaceuticals, Inc. to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021

Independent Director Daniel Welch has left the company

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2021

First quarter 2021 earnings released: US$1.22 loss per share (vs US$2.86 loss in 1Q 2020)

CFO, Treasurer & Principal Accounting Officer has left the company